These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2571713)

  • 1. CI-943, a potential antipsychotic agent. II. Neurochemical effects.
    Pugsley TA; Coughenour LL; Myers SL; Shih YH; Courtland GG; Berghoff W; Stewart SF
    J Pharmacol Exp Ther; 1989 Oct; 251(1):113-22. PubMed ID: 2571713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CI-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity.
    Meltzer LT; Christoffersen CL; Heffner TG; Freeman AS; Chiodo LA
    J Pharmacol Exp Ther; 1989 Oct; 251(1):123-30. PubMed ID: 2571714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
    J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
    Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
    J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
    Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
    J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of fluperlapine compared with clozapine.
    Eichenberger E
    Arzneimittelforschung; 1984; 34(1A):110-3. PubMed ID: 6145425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies.
    Wachtel SR; White FJ
    J Pharmacol Exp Ther; 1988 Jan; 244(1):410-6. PubMed ID: 2891845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
    Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of BMY 14802, a potential antipsychotic drug, on rat brain dopaminergic function.
    Matthews RT; McMillen BA; Sallis R; Blair D
    J Pharmacol Exp Ther; 1986 Oct; 239(1):124-31. PubMed ID: 2876091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats.
    Haleem DJ; Batool F; Khan NH; Kamil N; Ali O; Saify ZS; Haleem MA
    Med Sci Monit; 2002 Sep; 8(9):BR354-61. PubMed ID: 12218936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
    Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA
    Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of supidimide on brain neurotransmitter systems of rats and mice.
    Hennies HH; Günzler WA; Flohé L
    Arzneimittelforschung; 1984; 34(11):1471-80. PubMed ID: 6084511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of amfonelic acid with antipsychotic drugs on dopaminergic neurons.
    Gudelsky GA; Nwajei EE; Defife K; Nash JF
    Synapse; 1992 Dec; 12(4):304-11. PubMed ID: 1361248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of acute and chronic clozapine and haloperidol on in vitro release of acetylcholine and dopamine from striatum and nucleus accumbens.
    Compton DR; Johnson KM
    J Pharmacol Exp Ther; 1989 Feb; 248(2):521-30. PubMed ID: 2918468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action.
    Hertel P
    Synapse; 2006 Dec; 60(7):543-52. PubMed ID: 16952163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.
    Krisch I; Bole-Vunduk B; Pepelnak M; Lavric B; Ocvirk A; Budihna MV; Sket D
    J Pharmacol Exp Ther; 1994 Oct; 271(1):343-52. PubMed ID: 7965734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
    Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL
    J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.